The NRE is the non randomized extension of the RDT. The original RDT design was based on RECIST responses upon randomization and didn't incorporate the bone scan phenomenon. The NRE extension was designed to allow continuous dosing to all prostate cancer patients without fear of being randomized off drug.
Sat Jun 1, 2013 9:00am
Exelixis announces presentation of updated Phase 2 Data for Cabozantinib in men with heavily pretreated Metastatic Castration Resistant Prostate Cancer. With median overall survival of 10.8 months in a population where 73% of patients had 2+ prior therapies.